About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: SVA
- Previous Close: $5.63
- 50 Day Moving Average: $5.790
- 200 Day Moving Average: $5.921
- 52-Week Range: $5.25 - $6.64
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 112.50
- P/E Growth: 0.000
- Market Cap: $320.44M
- Outstanding Shares: 56,968,000
- Beta: 0.29
- Net Margins: -7.09%
- Return on Equity: -6.81%
- Return on Assets: -4.54%
Companies Related to Sinovac Biotech:
- Debt-to-Equity Ratio: 0.05%
- Current Ratio: 1.91%
- Quick Ratio: 1.61%
Consensus Ratings for Sinovac Biotech (NASDAQ:SVA) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Sinovac Biotech (NASDAQ:SVA)
No equities research coverage for this company has been tracked by MarketBeat.com
What is Sinovac Biotech's stock symbol?
Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."
When will Sinovac Biotech announce their earnings?
Sinovac Biotech is scheduled to release their next quarterly earnings announcement on Monday, April, 3rd 2017.
Who owns Sinovac Biotech stock?
Sinovac Biotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include SAIF Advisors Ltd (18.92%), Orbimed Advisors LLC (4.68%), Renaissance Technologies LLC (2.68%), Two Sigma Investments LP (0.20%), State Street Corp (0.07%) and GLG Partners LP (0.04%).
Who sold Sinovac Biotech stock? Who is selling Sinovac Biotech stock?
Sinovac Biotech's stock was sold by a variety of institutional investors in the last quarter, including GLG Partners LP and Guggenheim Capital LLC.
Who bought Sinovac Biotech stock? Who is buying Sinovac Biotech stock?
Sinovac Biotech's stock was acquired by a variety of institutional investors in the last quarter, including SAIF Advisors Ltd, Renaissance Technologies LLC, Two Sigma Investments LP and State Street Corp.
How do I buy Sinovac Biotech stock?
Shares of Sinovac Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Sinovac Biotech stock cost?
One share of Sinovac Biotech stock can currently be purchased for approximately $5.63.